

Pfizer Ltd

Revision date: 09-Sep-2011 Version: 2.0 Page 1 of 6

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161 Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

Material Name: Daunorubicin hydrochloride for injection

Trade Name: Daunoblastin Chemical Family: Mixture

Intended Use: Pharmaceutical product used as Antineoplastic

2. HAZARDS IDENTIFICATION

Appearance: Liquid

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

Short Term: Harmful if swallowed (based on components) . Drugs of this class have been associated with

rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at

increased risk from exposure.

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on testes

and the developing fetus.

Known Clinical Effects: Effects on blood and blood-forming organs have also occurred.

EU Indication of danger: Not classified

Australian Hazard Classification (NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

Material Name: Daunorubicin hydrochloride for injection Page 2 of 6

Revision date: 09-Sep-2011 Version: 2.0

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Daunorubicin Hydrochloride	23541-50-6	245-723-4	Xn;R22	< 0.5
			Repr. Cat. 2: R60-	
			61	
			Carc. Cat. 3;R40	
			Muta. Cat. 3;R68	

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Water for injection	7732-18-5	231-791-2	Not Listed	*
Sodium chloride	7647-14-5	231-598-3	Not Listed	*

Additional Information: * Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

area thoroughly.

D700007

Material Name: Daunorubicin hydrochloride for injection

Revision date: 09-Sep-2011 Version: 2.0

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

Page 3 of 6

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Restrict access to work area. Avoid breathing vapor or mist. Avoid contact with eyes, skin and

clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. It is recommended that all operations be fully

enclosed and no air recirculated.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Daunorubicin Hydrochloride

Pfizer OEL TWA-8 Hr: 0.1 μg/m³

Sodium chloride

Latvia OEL - TWA 5 mg/m³
Lithuania OEL - TWA 5 mg/m³

Analytical Method: Analytical method available for daunorubicin. Contact Pfizer Inc for further information.

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental

legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Hands: Impervious, disposable gloves (double suggested) are recommended if skin contact with drug

product is possible and for bulk processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious disposable protective clothing is recommended if skin contact with drug product is

possible and for bulk processing operations.

Respiratory protection: If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate

respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:LiquidColor:ColorlessMolecular Formula:MixtureMolecular Weight:Mixture

Page 4 of 6

Material Name: Daunorubicin hydrochloride for injection

Revision date: 09-Sep-2011 Version: 2.0

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Daunorubicin Hydrochloride

Rat Oral LD 50 336 mg/kg

Rat Para-periosteal LD50 13 mg/kg Rat Intraperitoneal LD50 20 mg/kg Mouse Oral LD50 205 mg/kg Mouse Intravenous LD50 8.6 mg/kg

Sodium chloride

Rat Oral LD50 3000 mg/kg Mouse Oral LD50 4000 mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium chloride

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Daunorubicin Hydrochloride

Embryo / Fetal Development Rabbit Oral 0.05 mg/kg/day LOAEL Teratogenic, Fetotoxicity

Embryo / Fetal Development Rat Oral 4 mg/kg/day LOAEL Teratogenic

Embryo / Fetal Development Rabbit Intravenous 1.5 mg/kg LOAEL Fetotoxicity, Fertility

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Daunorubicin Hydrochloride

In Vitro Bacterial Mutagenicity (Ames) Salmonella, E. coli Positive

In Vitro Cytogenetics Human Lymphocytes Positive

In Vivo Sister Chromatid Exchange Mouse Bone marrow Positive

In Vitro Micronucleus Human Lymphocytes Positive

Carcinogen Status: See below

Daunorubicin Hydrochloride

IARC: 2B - Possibly Carcinogenic to Humans

Material Name: Daunorubicin hydrochloride for injection

Revision date: 09-Sep-2011 Version: 2.0

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

Page 5 of 6

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A Class D, Division 1, Subdivision B



Daunorubicin Hydrochloride California Proposition 65 Australia (AICS): EU EINECS/ELINCS List

developmental toxicity initial date 7/1/90 Present 245-723-4

Material Name: Daunorubicin hydrochloride for injection

Revision date: 09-Sep-2011 Version: 2.0

15. REGULATORY INFORMATION

Water for injection

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

Sodium chloride

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS/ELINCS List

Present
231-598-3

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R22 - Harmful if swallowed.

R40 - Limited evidence of a carcinogenic effect

R60 - May impair fertility.

R61 - May cause harm to the unborn child. R68 - Possible risks of irreversible effects.

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 2 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal

Protection. Updated Section 10 - Stability and Reactivity. Updated Section 4 - First Aid Measures. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 -

Page 6 of 6

Handling and Storage. Updated Section 15 - Regulatory Information.

Prepared by: Product Stewardship Hazard Communication

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet
